# EDGAR Filing Document

**Accession Number:** 0001479615
**File Stem:** 0001193125-25-174958
**Filing Date:** 2025-8
**Character Count:** 17521
**Document Hash:** bc7e0dc4747a8064e4fdb087ae507952
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-174958.hdr.sgml**: 20250807

**ACCESSION NUMBER**: 0001193125-25-174958

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250807

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250807

**DATE AS OF CHANGE**: 20250807

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silence Therapeutics plc
- **CENTRAL INDEX KEY:** 0001479615
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39487
- **FILM NUMBER:** 251191631

**BUSINESS ADDRESS:**
- **STREET 1:** 72 HAMMERSMITH ROAD
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W14 8TH
- **BUSINESS PHONE:** 44-0-20-3457 6900

**MAIL ADDRESS:**
- **STREET 1:** 72 HAMMERSMITH ROAD
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W14 8TH

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): August 7, 2025

## Silence Therapeutics plc

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **England and Wales** | **001-39487** | **Not Applicable** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

---

| | |
|:---|:---|
| **72 Hammersmith Road**<br>**London**<br>**United Kingdom** | **W14 8TH** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

#### +44 20 3457 6900

#### (Registrant's telephone number, including area code)

#### Not Applicable

#### (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| American Depositary Shares, each representing 3 ordinary shares, nominal value £0.05 per share | SLN | The Nasdaq Stock Market LLC |
| Ordinary share, nominal value £0.05 per share\* | \* | The Nasdaq Stock Market LLC |

---

\* *Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.*

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02.** | **Results of Operations and Financial Condition.** |

---

On August 7, 2025, Silence Therapeutics plc (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2025, as well as recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference.

The information in this Item 2.02 of this Current Report on 8-K, including Exhibits 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit** <br>**No.** | **Description** |
| 99.1 | [Press Release dated August 7, 2025.](d14149dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SILENCE THERAPEUTICS PLC** | **SILENCE THERAPEUTICS PLC** |
| Dated: August 7, 2025 | By: | /s/ Craig Tooman |
|  | Name: | Craig Tooman |
|  | Title: | President and Chief Executive Officer (*Principal Executive Officer*) |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g14149g0806234234175.jpg)

**Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights** 

*• Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for* 

*Divesiran as First-in-Class siRNA in PV* 

*• SANRECO Phase 2 Study On-Track for Complete Enrollment by Year-End 2025* 

7 August 2025

LONDON, Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the second quarter ended June 30, 2025, and reviewed recent business highlights.

"The updated data we presented at EHA this past quarter were highly encouraging and supportive of the therapeutic potential of divesiran as a first-in-class siRNA in PV," said Craig Tooman, President and Chief Executive Officer at Silence. "The SANRECO Phase 2 trial of divesiran in PV patients continues to progress towards full enrollment this year and remains our top priority."

Rhonda Hellums, Silence's Chief Financial Officer, said, "We are continuing to prioritize investments in key areas where we see the highest potential to deliver near term value, including ensuring the successful completion of the SANRECO Phase 2 trial enrollment by year-end. We ended the quarter with approximately $114.2 million in cash and cash equivalents and short-term investments and are reiterating our cash runway guidance into 2028."

**<u>Second Quarter 2025 & Recent Business Highlights</u>**

**Divesiran for Polycythemia Vera (PV)** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Presented updated data from the SANRECO Phase 1 study at the European Hematology Association (EHA) 2025 Annual
Congress, further supporting divesiran's compelling therapeutic profile, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Additional data showing that treatment with divesiran led to durable hematocrit control (<45%) and essentially
eliminated the need for phlebotomies in the targeted population.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Divesiran increased hepcidin and ferritin, resulting in elevation of iron body content and improved iron
deficiency.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Divesiran was well tolerated with no dose-limiting toxicities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Exceeded 50% enrollment in the Phase 2 portion of the SANRECO trial and remain on-track to complete enrollment by year-end 2025.

**Zerlasiran for Cardiovascular Disease** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Completed core Phase 3 readiness activities, including manufacturing and supply scale up. We continue to be in
dialogues with potential third-party partners for Phase 3 development of zerlasiran as well as potential future commercialization activities.

**Other R&D Updates** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Advanced extra-hepatic cell targeting of siRNA where we are seeing promising initial preclinical activity in mice
models. As a result, we are prioritizing our extra-hepatic activities and have decided to pause initiating a Phase 1 study of SLN548, our wholly owned siRNA for complement-mediated diseases.

------

![LOGO](g14149g0806234234175.jpg)

**Collaborations** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A Phase 1 study of our siRNA product candidate, SLN312, which is licensed to AstraZeneca, is ongoing.

**<u>Second Quarter 2025 Financial Highlights</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Cash Position:** Cash and cash equivalents, and short-term investments of $114.2 million as of
June 30, 2025, which are expected to fund our operational plans into 2028.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Research & Development Expenses:** R&D expenses were $17.6 million for the
quarter ended June 30, 2025, as compared to $13.8 million for the quarter ended June 30, 2024. The increase in R&D expenses was primarily driven by the advancement of our clinical trials and an increase in contract manufacturing
activities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **General & Administrative Expenses:** G&A expenses were $5.1 million for the
quarter ended June 30, 2025, as compared to $7.0 million for the quarter ended June 30, 2024. The decrease in G&A expenses was primarily due to a reduction in reporting and compliance requirements, as well as our efforts to
increase operating efficiencies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Net Loss:** Net loss was $27.4 million for the quarter ended June 30, 2025, as compared to
$19.8 million for the quarter ended June 30, 2024.

**About Silence Therapeutics** 

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD<sup>™</sup> platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https://www.silence-therapeutics.com/.

**Forward-Looking Statements** 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the Company's business strategy and plans, including the Company's clinical development activities and timelines; the therapeutic benefits of the Company's product candidates; the timing of patient enrollment of the SANRECO Phase 2 trial; the progression and advancement of collaborations; the Company's ability to deliver near term value; and the Company's anticipated extended cash runway. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company's history of net operating losses; the company's ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company's product candidates; the company's ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company's product candidates; the company's reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company's ability to adequately maintain intellectual property rights for its product

------

![LOGO](g14149g0806234234175.jpg)

candidates. These and other risks are described in greater detail under the section titled "Risk Factors" contained in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company's other filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

**Inquiries:** 

Silence Therapeutics plc Gem Hopkins, VP, IR and Corporate Communications <u>ir@silence-therapeutics.com</u> Tel: +1 (646) 637-3208

------

![LOGO](g14149g0806234234175.jpg)

**Silence Therapeutics plc** 

**Condensed Consolidated Balance Sheets** 

**(Unaudited, in thousands, except share and per share data)** 

---

| | | |
|:---|:---|:---|
|  | June 30,<br>2025 | December 31,<br>2024 |
|  **Current assets** |  |  |
|  Cash and cash equivalents | $41739 | $121330 |
|  Short-term investments | 72416 | 26004 |
|  R&D benefit receivable | 19957 | 24396 |
|  Other current assets | 14356 | 14664 |
|  Trade receivables | 85 | 972 |
|  **Total current assets** | **148553** | **187366** |
|  Property, plant and equipment | 1775 | 1818 |
|  Operating lease right-of-use assets | 58 | 157 |
|  Goodwill | 10617 | 9392 |
|  Other intangible assets | 317 | 312 |
|  Other long-term assets | 3913 | 3590 |
|  **Total assets** | $**165233** | $**202635** |
|  **Current liabilities** |  |  |
|  Contract liabilities | $(457) | $(306) |
|  Trade and other payables | (14311) | (16399) |
|  Operating lease liabilities, current |  | (117) |
|  **Total current liabilities** | **(14768)** | **(16822)** |
|  Contract liabilities | (56310) | (51790) |
|  **Total liabilities** | $**(71078)** | $**(68612)** |
|  Commitments and contingencies (Note 11) |  |  |
|  **Shareholders' equity** |  |  |
|  Ordinary shares - par value £0.05 per share; 141,701,848 shares issued at June 30, 2025 (December 31, 2024: 141,674,074) | (10290) | (10288) |
|  Additional paid-in capital | (615113) | (609560) |
|  Accumulated deficit | 529844 | 474044 |
|  Accumulated other comprehensive loss | 1404 | 11781 |
|  **Total shareholders' equity** | **(94155)** | **(134023)** |
|  **Total liabilities and shareholders' equity** | $**(165233)** | $**(202635)** |

---

------

![LOGO](g14149g0806234234175.jpg)

**Silence Therapeutics plc** 

**Condensed Consolidated Statements of Operations and Comprehensive Loss** 

**(Unaudited, in thousands, except share and per share data)** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended June 30,** | **Three months ended June 30,** | **Six months ended June 30,** | **Six months ended June 30,** |
|  | 2025 | 2024 | 2025 | 2024 |
|  Revenue | $224 | $756 | $366 | $16455 |
|  Cost of sales | (85) | (3333) | (139) | (6133) |
|  **Gross profit** | **139** | **(2577)** | **227** | **10322** |
|  Research and development costs | (17647) | (13802) | (38460) | (25647) |
|  General and administrative expenses | (5131) | (7009) | (12815) | (13644) |
|  Restructuring charges | (1324) |  | (1324) |  |
|  **Operating loss** | **(23963)** | **(23388)** | **(52372)** | **(28969)** |
|  Foreign currency (loss)/gain, net | (6613) | (222) | (10382) | 129 |
|  Other income, net | 861 | 1351 | 1830 | 2017 |
|  Benefit from R&D credit | 2371 | 2732 | 5050 | 5228 |
|  **Loss before income tax expense** | **(27344)** | **(19527)** | **(55874)** | **(21595)** |
|  Income tax expense | (10) | (228) | (10) | (472) |
|  **Net Loss** | $**(27354)** | $**(19755)** | $**(55884)** | $**(22067)** |
|  **Loss per share (basic and diluted)** | $(0.19) | $(0.14) | $(0.39) | $(0.16) |
|  **Weighted average shares outstanding (basic and diluted)** | 141696047 | 140208929 | 141687438 | 136045022 |

---